Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Merck & Company (MRK)
Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 262,904,880
  • Shares Outstanding, K 2,534,023
  • Annual Sales, $ 59,283 M
  • Annual Income, $ 14,519 M
  • 60-Month Beta 0.34
  • Price/Sales 4.44
  • Price/Cash Flow 11.69
  • Price/Book 6.49
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 17.54% ( -0.20%)
  • Historical Volatility 15.49%
  • IV Percentile 1%
  • IV Rank 1.17%
  • IV High 26.55% on 10/20/23
  • IV Low 17.43% on 09/01/23
  • Put/Call Vol Ratio 0.78
  • Today's Volume 12,483
  • Volume Avg (30-Day) 18,171
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 388,038
  • Open Int (30-Day) 356,938

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.15
  • Number of Estimates 8
  • High Estimate 1.88
  • Low Estimate -0.12
  • Prior Year 1.62
  • Growth Rate Est. (year over year) -90.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.80 +3.96%
on 11/29/23
106.57 -2.65%
on 12/06/23
-0.65 (-0.62%)
since 11/08/23
3-Month
99.14 +4.65%
on 10/19/23
109.67 -5.40%
on 09/13/23
-5.30 (-4.86%)
since 09/08/23
52-Week
96.36 +7.67%
on 01/24/23
119.65 -13.29%
on 05/03/23
-7.10 (-6.41%)
since 12/08/22

Most Recent Stories

More News
5 Dividend Stocks That Recently Increased Their Payouts

One stock increased its dividend by 25%.

PHM : 96.31 (+1.96%)
NKE : 115.91 (+0.96%)
MKC : 67.09 (-0.94%)
FAST : 62.29 (-0.11%)
MRK : 103.75 (-0.13%)
1 Penny Stock Insiders Are Buying with Both Hands

This 'Strong Buy'-rated penny stock has scored some major insider buying from C-suite insiders. Here's what investors need to know about this small-cap healthcare stock.

OPK : 1.6300 (+1.87%)
PFE : 28.78 (+0.52%)
MRK : 103.75 (-0.13%)
Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment...

ABBV : 149.28 (+0.89%)
JNJ : 154.42 (-0.63%)
MRK : 103.75 (-0.13%)
2 Healthcare Stocks That Could Make You Richer

Merck and Intuitive Surgical both still have bright futures ahead.

MRK : 103.75 (-0.13%)
ISRG : 310.42 (-0.37%)
Lexaria Bioscience (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with DehydraTECH(TM)

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is evaluating the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for the treatment...

NVO : 96.64 (-0.18%)
PFE : 28.78 (+0.52%)
MRK : 103.75 (-0.13%)
AZN : 63.25 (-0.41%)
LEXX : 1.3500 (-6.25%)
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

DTCFF : 1.8500 (unch)
DTC.CN : 2.8000 (+27.27%)
BMY : 50.31 (+0.30%)
NVS : 96.30 (+0.39%)
MRK : 103.75 (-0.13%)
RHHBY : 36.0000 (+1.18%)
3 S&P stocks with growth to weather a downturn

S&P 500 components Broadcom, McCormick and Merck stocks are diverse stocks worth tracking for investors seeking strong earnings and dividend growth.

AVGO : 944.30 (+2.39%)
XLK : 186.66 (+0.85%)
MKC : 67.09 (-0.94%)
MRK : 103.75 (-0.13%)
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?

There's a lot more at stake than bragging rights.

MRK : 103.75 (-0.13%)
BMY : 50.31 (+0.30%)
The 3 Best Dow Jones Stocks to Invest in Now, According to Wall Street

Analysts are bullish on these three dividend-paying Dow stocks, with consensus "Strong Buy" ratings and more upside expected for this diverse set of blue chips.

MRK : 103.75 (-0.13%)
UNH : 549.77 (+0.27%)
MSFT : 374.23 (+0.88%)
ORCL : 113.61 (+0.66%)
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
BMY : 50.31 (+0.30%)
GILD : 79.02 (+1.24%)
MRK : 103.75 (-0.13%)
PFE : 28.78 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 105.65
2nd Resistance Point 104.83
1st Resistance Point 104.29
Last Price 103.75
1st Support Level 102.93
2nd Support Level 102.11
3rd Support Level 101.57

See More

52-Week High 119.65
Fibonacci 61.8% 110.75
Fibonacci 50% 108.01
Fibonacci 38.2% 105.26
Last Price 103.75
52-Week Low 96.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar